According to new research findings in the Journal of Clinical Oncology, the addition of Gemzar® (gemcitabine) to Paraplatin® (carboplatin) improves progression-free survival among women who received previous therapies for the therapy of ovary cancer.

Ovary cancer is the eighth most common cancer among women. It is considered to be one of the most deadly cancers because the vast majority of patients are diagnosed once the cancer has already spread from the ovary. Approximately 90% of patients diagnosed with ovary cancer will experience a recurrence of their disease; long-term survival for these patients remains unfavorable.

Scientists from Europe, Canada, and the United States recently conducted a clinical trial to evaluate the addition of Gemzar to carboplatin in the therapy of women with recurrent ovary cancer. This trial included 356 patients who had received previous treatment with chemotherapy including either carboplatin or Platinol® (cisplatin). They had experienced a cancer recurrence at least six months following initial treatment. One group of patients was treated with Gemzar/carbolatin, and the other group of patients received carboplatin only.


Posted by: Andria    Source

---